SCHEMBL26813006

SCHEMBL26813006

O=S(=O)(Nc1nc(Oc2ccccc2)cc(-c2ccccc2)n1)c1cccnc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.50
▸ MAPK1 P28482 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ USP2 O75604 1/20 0.44
▸ USP8 P40818 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ ATM Q13315 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ TSHR P16473 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CYP11B1 P15538 1/20 0.43
▸ CYP11B2 P19099 1/20 0.43
▸ CKS1B P61024 1/20 0.43
▸ SKP2 Q13309 1/20 0.43
▸ KEAP1 Q14145 1/20 0.43
▸ NFE2L2 Q16236 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26806950 0.93 MAPT (0.53) MAPTMAPK1TDP1MEN1CYP1A2
SCHEMBL26806813 0.89 MAPT (0.61) MAPTMAPK1TDP1MEN1CYP1A2
SCHEMBL26813005 0.87 MAPT (0.56) MAPTMAPK1TDP1MEN1CYP1A2
SCHEMBL26810944 0.87 MAPT (0.53) MAPTMAPK1TDP1MEN1CYP1A2
SCHEMBL26812830 0.84 MAPT (0.57) MAPTMAPK1TDP1MEN1CYP1A2
SCHEMBL26806954 0.84 MAPT (0.55) MAPTMAPK1TDP1MEN1CYP1A2
SCHEMBL26810840 0.84 MAPT (0.49) MAPTMAPK1TDP1MEN1CYP1A2
SCHEMBL24310594 0.82 MAPT (0.57) MAPTMAPK1TDP1MEN1CYP1A2
SCHEMBL24309572 0.82 MAPT (0.50) MAPTMAPK1TDP1MEN1CYP1A2
SCHEMBL24310185 0.82 PGR (0.58) MAPTMAPK1TDP1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B MAPT 4864/4885MAPK1 3810/4885TDP1 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback